Beth Coyle

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8597006/publications.pdf

Version: 2024-02-01

54	9,380	394421	214800
papers	citations	19 h-index	47 g-index

55	55	55	15801
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Establishing an In Vitro 3D Spheroid Model to Study Medulloblastoma Drug Response and Tumor Dissemination. Current Protocols, 2022, 2, e357.	2.9	9
2	Y-Box Binding Protein-1: A Neglected Target in Pediatric Brain Tumors?. Molecular Cancer Research, 2021, 19, 375-387.	3.4	4
3	<scp>3D</scp> hydrogels reveal medulloblastoma subgroup differences and identify extracellular matrix subtypes that predict patient outcome. Journal of Pathology, 2021, 253, 326-338.	4.5	6
4	ABCB1 inhibition provides a novel therapeutic target to block TWIST1-induced migration in medulloblastoma. Neuro-Oncology Advances, 2021, 3, vdab030.	0.7	2
5	3D spheroid models of paediatric SHH medulloblastoma mimic tumour biology, drug response and metastatic dissemination. Scientific Reports, 2021, 11, 4259.	3.3	20
6	BLBP Is Both a Marker for Poor Prognosis and a Potential Therapeutic Target in Paediatric Ependymoma. Cancers, 2021, 13, 2100.	3.7	5
7	Chemosensitization of Temozolomide-Resistant Pediatric Diffuse Midline Glioma Using Potent Nanoencapsulated Forms of a N(3)-Propargyl Analogue. ACS Applied Materials & Interfaces, 2021, 13, 35266-35280.	8.0	15
8	DDRE-37. YB-1 AS A BIOMARKER FOR DRUG RESISTANCE AND TUMOUR PROGRESSION IN MEDULLOBLASTOMA. Neuro-Oncology, 2021, 23, vi82-vi82.	1.2	0
9	Leptomeningeal malignancy of childhood: sharing learning between childhood leukaemia and brain tumour trials. The Lancet Child and Adolescent Health, 2020, 4, 242-250.	5.6	6
10	MBRS-28. EXOSOMES DRIVE MEDULLOBLASTOMA METASTASIS IN A MMP2 AND EMMPRIN DEPENDENT MANNER. Neuro-Oncology, 2020, 22, iii403-iii403.	1.2	0
11	MBRS-27. EXOSOMES CARRY DISTINCT miRNAs THAT DRIVE MEDULLOBLASTOMA PROGRESSION. Neuro-Oncology, 2020, 22, iii403-iii403.	1.2	0
12	MBRS-42. YB-1 - A NOVEL THERAPEUTIC TARGET IN HIGH-RISK MEDULLOBLASTOMA?. Neuro-Oncology, 2020, 22, iii405-iii405.	1.2	0
13	A role for ABCB1 in prognosis, invasion and drug resistance in ependymoma. Scientific Reports, 2019, 9, 10290.	3.3	13
14	A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells. Cellular Oncology (Dordrecht), 2018, 41, 319-328.	4.4	53
15	MBRS-46. JERANTININE: A NOVEL TUMOUR-SPECIFIC ALKALOID FOR THE TREATMENT OF PAEDIATRIC MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i138-i138.	1.2	1
16	MBRS-49. USING SENSITIVE MAGNETIC RESONANCE IMAGING TECHNIQUES TO IMPROVE THE RISK STRATIFICATION OF PATIENTS WITH METASTATIC MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i138-i139.	1.2	0
17	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018, 7, 1535750.	12.2	6,961
18	MBRS-39. TWIST1 PLAYS A REGULATORY ROLE IN MEDULLOBLASTOMA METASTASIS. Neuro-Oncology, 2018, 20, i136-i137.	1.2	0

#	Article	IF	Citations
19	MBRS-47. ESTABLISHMENT OF A 3D SPHEROID-BASED MODEL OF MEDULLOBLASTOMA THAT RECAPITULATES TUMOUR GROWTH, DRUG RESPONSE AND MIGRATION. Neuro-Oncology, 2018, 20, i138-i138.	1.2	0
20	Wilms' Tumor Protein 1 and Enzymatic Oxidation of 5-Methylcytosine in Brain Tumors: Potential Perspectives. Frontiers in Cell and Developmental Biology, 2018, 6, 26.	3.7	7
21	Medulloblastoma and ependymoma cells display increased levels of 5-carboxylcytosine and elevated TET1 expression. Clinical Epigenetics, 2017, 9, 18.	4.1	14
22	Immunostaining for DNA Modifications: Computational Analysis of Confocal Images. Journal of Visualized Experiments, 2017, , .	0.3	5
23	Long-term exposure to irinotecan reduces cell migration in glioma cells. Journal of Neuro-Oncology, 2016, 127, 455-462.	2.9	1
24	In vitro models of medulloblastoma: Choosing the right tool for the job. Journal of Biotechnology, 2016, 236, 10-25.	3.8	165
25	Data on the number and frequency of scientific literature citations for established medulloblastoma cell lines. Data in Brief, 2016, 9, 696-698.	1.0	7
26	ABCB1 in children's brain tumours. Biochemical Society Transactions, 2015, 43, 1018-1022.	3.4	18
27	Overcoming multiple drug resistance mechanisms in medulloblastoma. Acta Neuropathologica Communications, 2014, 2, 57.	5.2	49
28	The role of the WNT/Î²-catenin pathway in central nervous system primitive neuroectodermal tumours (CNS PNETs). British Journal of Cancer, 2013, 108, 2130-2141.	6.4	15
29	PI3K Pathway Activation Provides a Novel Therapeutic Target for Pediatric Ependymoma and Is an Independent Marker of Progression-Free Survival. Clinical Cancer Research, 2013, 19, 6450-6460.	7.0	17
30	Copy Number Gain of 1q25 Predicts Poor Progression-Free Survival for Pediatric Intracranial Ependymomas and Enables Patient Risk Stratification: A Prospective European Clinical Trial Cohort Analysis on Behalf of the Children's Cancer Leukaemia Group (CCLG), SociÃ©tÃ© FranÃ§aise d'Oncologie PÃ©diatrique (SFOP), and International Society for Pediatric Oncology (SIOP). Clinical Cancer Research, 2012, 18, 2001-2011.	7.0	111
31	WNT/Î²-catenin pathway activation in Myc immortalised cerebellar progenitor cells inhibits neuronal differentiation and generates tumours resembling medulloblastoma. British Journal of Cancer, 2012, 107, 1144-1152.	6.4	19
32	Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death. Acta Neuropathologica, 2012, 123, 711-725.	7.7	38
33	CD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma. Acta Neuropathologica, 2012, 124, 99-110.	7.7	51
34	Pediatric brain tumor cancer stem cells: cell cycle dynamics, DNA repair, and etoposide extrusion. Neuro-Oncology, 2011, 13, 70-83.	1.2	60
35	Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas. Neuro-Oncology, 2011, 13, 212-222.	1.2	103
36	Pediatric high-grade glioma: identification of poly(ADP-ribose) polymerase as a potential therapeutic target. Neuro-Oncology, 2011, 13, 1171-1177.	1.2	17

#	Article	IF	Citations
37	RASSF1A and the BH3-only mimetic ABT-737 promote apoptosis in pediatric medulloblastoma cell lines. Neuro-Oncology, 2011, 13, 1265-1276.	1.2	15
38	Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma. Neuro-Oncology, 2011, 13, 866-879.	1.2	67
39	Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature, 2010, 466, 632-636.	27.8	324
40	Integrated Molecular Genetic Profiling of Pediatric High-Grade Gliomas Reveals Key Differences With the Adult Disease. Journal of Clinical Oncology, 2010, 28, 3061-3068.	1.6	558
41	Histone Deacetylase Inhibition Attenuates Cell Growth with Associated Telomerase Inhibition in High-Grade Childhood Brain Tumor Cells. Molecular Cancer Therapeutics, 2010, 9, 2568-2581.	4.1	34
42	Pediatric Ependymoma: Biological Perspectives. Molecular Cancer Research, 2009, 7, 765-786.	3.4	162
43	Investigation of chromosome 1q reveals differential expression of members of the S100 family in clinical subgroups of intracranial paediatric ependymoma. British Journal of Cancer, 2008, 99, 1136-1143.	6.4	30
44	Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma. Neuro-Oncology, 2008, 10, 675-689.	1.2	90
45	Strategies to investigate gene expression and function in granule cells. Cerebellum, 2005, 4, 271-278.	2.5	6
46	Novel strategy to study gene expression and function in developing cerebellar granule cells. Journal of Neuroscience Methods, 2004, 132, 149-160.	2.5	16
47	Regulation of apoptosis by peroxisome proliferators. Toxicology Letters, 2004, 149, 37-41.	0.8	17
48	Early Drug Safety Evaluation: Biomarkers, Signatures, and Fingerprints. Drug Metabolism Reviews, 2003, 35, 269-275.	3.6	18
49	Characterization of the Transforming Growth Factor-Î²1-induced Apoptotic Transcriptome in FaO Hepatoma Cells. Journal of Biological Chemistry, 2003, 278, 5920-5928.	3.4	34
50	Concurrence of Pendred Syndrome, Autoimmune Thyroiditis, and Simple Goiter in One Family. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2736-2738.	3.6	19
51	Concurrence of Pendred Syndrome, Autoimmune Thyroiditis, and Simple Goiter in One Family. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2736-2738.	3.6	6
52	Genomic structure of the human congenital chloride diarrhea (CLD) gene. Gene, 1998, 214, 87-93.	2.2	33
53	Thyroid peroxidase: evidence for disease gene exclusion in Pendred's syndrome. Clinical Endocrinology, 1996, 44, 441-446.	2.4	13
54	Pendred syndrome (goitre and sensorineural hearing loss) maps to chromosome 7 in the region containing the nonsyndromic deafness gene DFNB4. Nature Genetics, 1996, 12, 421-423.	21.4	146